DK3503890T3 - Anvendelse af pridopidin til behandling af dystonier - Google Patents

Anvendelse af pridopidin til behandling af dystonier Download PDF

Info

Publication number
DK3503890T3
DK3503890T3 DK17844432.9T DK17844432T DK3503890T3 DK 3503890 T3 DK3503890 T3 DK 3503890T3 DK 17844432 T DK17844432 T DK 17844432T DK 3503890 T3 DK3503890 T3 DK 3503890T3
Authority
DK
Denmark
Prior art keywords
pridopidine
dystonias
treatment
Prior art date
Application number
DK17844432.9T
Other languages
Danish (da)
English (en)
Inventor
Michael Hayden
Juha-Matti Savola
Eli Eyal
Beth Borowsky
Igor D Grachev
Mark Forrest Gordon
Spyridon Papapetropoulos
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Application granted granted Critical
Publication of DK3503890T3 publication Critical patent/DK3503890T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17844432.9T 2016-08-24 2017-08-24 Anvendelse af pridopidin til behandling af dystonier DK3503890T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395319P 2016-09-15 2016-09-15
PCT/US2017/048458 WO2018039475A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating dystonias

Publications (1)

Publication Number Publication Date
DK3503890T3 true DK3503890T3 (da) 2025-01-27

Family

ID=61246309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17844432.9T DK3503890T3 (da) 2016-08-24 2017-08-24 Anvendelse af pridopidin til behandling af dystonier

Country Status (12)

Country Link
US (2) US11826361B2 (OSRAM)
EP (1) EP3503890B1 (OSRAM)
JP (2) JP7278210B2 (OSRAM)
CN (1) CN110012661A (OSRAM)
AU (1) AU2017315781B2 (OSRAM)
BR (1) BR112019003731A2 (OSRAM)
CA (1) CA3035099C (OSRAM)
DK (1) DK3503890T3 (OSRAM)
ES (1) ES3009437T3 (OSRAM)
MX (1) MX2019002190A (OSRAM)
PL (1) PL3503890T3 (OSRAM)
WO (1) WO2018039475A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
CA3035092C (en) 2016-08-24 2022-05-31 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating functional decline
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
JP7603713B2 (ja) * 2020-05-04 2024-12-20 プリレニア ニューロセラピューティクス リミテッド 選択的s1rアゴニストを使用するウイルス感染、疾患、又は障害の治療
CN120569199A (zh) * 2022-12-27 2025-08-29 普瑞尼亚神经治疗有限公司 普利多匹定用于治疗青少年亨廷顿病
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function
WO2025188979A1 (en) * 2024-03-06 2025-09-12 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
ES2346452T3 (es) * 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
JP5393654B2 (ja) 2007-04-12 2014-01-22 イヴァックス インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツンク 改善された心血管副作用プロフィールを呈する、ドーパミン受容体安定剤/調節剤のn−オキシド誘導体及び/又はジ−n−オキシド誘導体
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
MX377576B (es) * 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017015615A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
CA3015512C (en) 2016-02-24 2024-01-16 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
CA3035092C (en) 2016-08-24 2022-05-31 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating functional decline
WO2018053287A1 (en) 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
DK4005570T3 (da) 2016-09-16 2024-08-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse behandling af retts syndroe
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
AU2018210145B2 (en) 2017-01-20 2023-06-29 Agency For Science, Technology And Research Use of pridopidine for the treatment of fragile X syndrome
BR112020003119A2 (pt) 2017-08-14 2020-10-13 Prilenia Neurotherapeutics Ltd. método de tratamento de esclerose lateral amiotrófica com pridopidina
EP3678664A1 (en) 2017-09-08 2020-07-15 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Also Published As

Publication number Publication date
PL3503890T3 (pl) 2025-03-24
CA3035099A1 (en) 2018-03-01
EP3503890B1 (en) 2024-12-18
JP2019524897A (ja) 2019-09-05
WO2018039475A1 (en) 2018-03-01
US11826361B2 (en) 2023-11-28
US20240075021A1 (en) 2024-03-07
ES3009437T3 (en) 2025-03-26
AU2017315781A1 (en) 2019-04-11
EP3503890A4 (en) 2020-05-06
CN110012661A (zh) 2019-07-12
CA3035099C (en) 2023-01-17
EP3503890A1 (en) 2019-07-03
JP7278327B2 (ja) 2023-05-19
MX2019002190A (es) 2019-09-11
AU2017315781B2 (en) 2021-01-28
JP2021119189A (ja) 2021-08-12
US20190192496A1 (en) 2019-06-27
BR112019003731A2 (pt) 2019-07-16
JP7278210B2 (ja) 2023-05-19
WO2018039475A8 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
DK3785717T3 (da) Fremgangsmåder til behandling af coronaviridae-infektioner
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3490582T3 (da) Sammensætninger til anvendelse i behandling af myelofibrose
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3524255T3 (da) Sammensætning til behandling af acne
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3318115T3 (da) Maskine til behandling af svinegylle
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3261661T3 (da) Menotropin til behandling af infertilitet